miR-3960 from Mesenchymal Stem Cell-Derived Extracellular Vesicles Inactivates SDC1/Wnt/β-Catenin Axis to Relieve Chondrocyte Injury in Osteoarthritis by Targeting PHLDA2

Figure 7

miR-3960 PHLDA2/SDC1/Wnt/β-Catenin axis to suppress chondrocyte inflammation and ECM degradation. Chondrocytes were treated with IL-1β, miR-3960 mimic, and/or oe-SDC1. (a) miR-3960 expression and mRNA levels of PHLDA2, SDC1, and β-catenin in chondrocytes determined by RT-qPCR. (b) Protein levels of PHLDA2, SDC1, and β-catenin in chondrocytes determined by immunoblotting. (c) Cell proliferation assessed by CCK8 assay. (d) Apoptosis assessed by flow cytometry. (e) Protein levels of collagen II, aggrecan, MMP13, and ADAMTS5 in chondrocytes measured by immunoblotting. (f) Levels of IL-6 and TNF-α in chondrocytes measured by ELISA. vs. chondrocytes without treatment; ^# vs. chondrocytes treated with IL-1β+mimic-NC; & vs. chondrocytes treated with IL-1β+miR-3960 mimic+oe-NC. Data are shown as the of three technical replicates. Data between two groups were compared by independent t-test. Data comparisons among multiple groups were analyzed by the one-way ANOVA with Tukey’s post hoc test, and comparison of data at different time points was analyzed using repeated measurement ANOVA with Tukey’s post hoc test.

(a)

(b)

(c)

(d)

(e)

(f)